Confronta i metodi

	Questionario sulla Qualità della Vita Specifica per la Menopausa	Scala per il Dolore Pelvico Femminile	Strumento di screening per i sintomi premestruali
Campo	Ostetricia e ginecologia	Ostetricia e ginecologia	Ostetricia e ginecologia
Famiglia	Process / pipeline	Process / pipeline	Process / pipeline
Anno di origine	1996	2001	2003
Ideatore	Hilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H.	Multiple developers	Steiner, M., Macdougall, M., & Brown, E.
Tipo	Self-report	Self-report	Self-report
Fonte seminale	Hilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H., Lethargy, S., & Improvement, T. (1996). A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas, 24(3), 161-175.	Jones, G. L., Kennedy, S. H., Barnard, A., Wong, J., & Jenkinson, C. (2001). Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. Obstetrics & Gynecology, 98(2), 258-264.	Steiner, M., Macdougall, M., & Brown, E. (2003). The Premenstrual Symptoms Screening Tool (PSST) for clinicians. Archives of Women's Mental Health, 6(3), 203-209.
Alias	MENQOL, Menopause Quality of Life	FPPS, Pelvic Pain Questionnaire	PSST, Premenstrual Symptom Screening
Correlati	3	3	3
Sintesi	The Menopause-Specific Quality of Life Questionnaire (MENQOL) is a 29-item self-report instrument designed to assess quality of life in women experiencing menopausal symptoms. Developed by Hilditch and colleagues in 1996, the MENQOL captures four interrelated symptom domains: vasomotor symptoms (hot flushes, night sweats), psychosocial symptoms (mood, stress, anxiety), physical symptoms (fatigue, aches, sleep), and sexual symptoms. It is the primary menopause-specific outcome measure used in hormone replacement therapy trials and menopause research.	The Female Pelvic Pain Scale (FPPS) is a standardized self-report instrument designed to assess the severity and functional impact of pelvic pain conditions in women, including dysmenorrhea, pelvic inflammatory disease, interstitial cystitis, and pelvic pain of unclear etiology. By measuring pain intensity, location, timing, and associated functional limitations, the FPPS enables clinicians to quantify baseline pain burden and track treatment response.	The Premenstrual Symptoms Screening Tool (PSST) is a brief, 19-item self-report questionnaire designed to screen for premenstrual dysphoric disorder (PMDD) and assess the severity of premenstrual symptoms. Developed by Steiner, Macdougall, and Brown in 2003, the PSST efficiently identifies women with clinically significant cyclical mood and physical symptoms warranting diagnostic evaluation and potential pharmacological or psychological treatment.